Employer health cost crunch is worse than projected
Add Axios as your preferred source to
see more of our stories on Google.

Illustration: Annelise Capossela/Axios
There's new evidence that double-digit health cost increases were hitting employers well before the forecasts of big spikes for 2027 — forcing big changes in workplace coverage for millions of Americans.
Why it matters: The findings offer a higher-resolution view of how much health spending is putting a drag on the labor market and increasing affordability concerns for the approximately 160 million Americans who get coverage through work.
- They also show how factors like surprise billing disputes, more cancer diagnoses and expensive specialty drugs are combining to exert cost pressure, with no immediate relief in sight.
Driving the news: A new Gallagher benefits survey of more than 3,700 firms found 36% of the companies reported premium increases of 10% or more during their most recent renewal.
- Pharmacy costs account for a quarter or more of some companies' total health spending.
- Cancer care is the No. 1 cost driver for about 7 in 10 firms.
- The survey, fielded from January to March, also found employers are trying to avoid saddling workers with a disproportionate share of rising costs while struggling to balance the quality of care with their financial risk.
"The last two renewal cycles have been unlike anything we've ever seen before," said Robby White, Gallagher's U.S. benefits business line leader. "It's unsustainable, obviously. Every additional dollar that an employer spends on health care, they can't spend on their employees."
Between the lines: The 2027 coverage year was already shaping up to be painful for many employers. Projections are showing premium spikes due to rising demand for health services, more chronic disease and increased use of drugs like GLP-1s.
- In fact, double-digit premium increases for both the 2026 and 2027 plan years suggest there are more underlying causes, according to benefits experts.
- One leading factor is chronic disease: More people are being diagnosed with cancer at a younger age, and advanced treatments and related care can result in $10,000 a month in expenses or claims.
- Drug costs also are surging — and not just because of demand for GLP-1s. The high cost of specialty drugs for chronic or rare conditions is prompting companies to scrutinize the way formularies are designed and how well pharmacy benefit managers administer their benefits.
White said another big cost driver is the No Surprises Act, which shielded consumers from large, unexpected medical bills but also created an expensive arbitration process.
- The arbitration has added administrative costs and is giving providers big payouts, which add millions in costs for large employers that self-fund their health plans.
- That's an assessment shared by big health insurers, which say the surprise billing law is creating unintended financial consequences.
- "The [independent dispute resolution] process has now become a top-three single driver of health care cost increases for employers," Aetna president Steve Nelson told Axios, adding the company wants to work with Congress to overhaul the system.
The big picture: In a volatile health market, more employers are self-insuring and directly paying medical claims to have greater visibility and control over health costs, the Gallagher survey finds.
- As workers get tired of high deductibles, some employers are testing copay-only plans, which vary out-of-pocket costs by medical service and steer workers to providers deemed to be providing the most value. Part of this involves more digital tools to help patients decide.
- They're also re-evaluating their relationships with pharmacy benefit managers in response to rising drug costs, leading to what White says is a "huge shift" away from the big three PBMs — CVS Caremark, Optum Rx and Express Scripts.
- On GLP-1s, Gallagher says the question isn't whether the drugs are effective, but whether coverage is financially sustainable. More companies are exploring direct-to-consumer sales through outside vendors and giving employees debit cards or defined subsidies.
What we're watching: Benefits experts are waiting to see how much congressionally mandated changes to PBMs' business practices bring down drug prices and improve transparency.
- They're also watching the growing number of worker lawsuits against plan sponsors, alleging they breached their fiduciary duty by failing to negotiate reasonable prescription drug prices or keep fees reasonable.
Caitlin Owens contributed to this story.
